Home/Pipeline/Breast Cancer Consortium

Breast Cancer Consortium

Breast Cancer

UnknownActive

Key Facts

Indication
Breast Cancer
Phase
Unknown
Status
Active
Company

About Criterium

Criterium is a long-established, privately-held CRO that has carved out a specialized niche in oncology clinical research through its innovative Oncology Consortia model. The company combines hands-on operational expertise with technology solutions like interactive voice/web response (IVR/IWR) and ePRO to manage complex trials efficiently. Its core strategy involves forming disease-specific consortia with top-tier universities and cancer centers, enabling rapid patient recruitment and high-quality data generation for pharmaceutical and biotech sponsors. While primarily a service provider, its deep integration into therapeutic development gives it significant insight into the oncology pipeline landscape.

View full company profile

Other Breast Cancer Drugs

DrugCompanyPhase
Antifibrotic Therapy ProgramMeCo DiagnosticsPre-clinical
inPROBE for HER2SDS OpticClinical Investigation
ACT‑BC1AnthrocellPreclinical
APA-1000 Breast Thermotherapy SystemMedifocusPhase III
Early‑Detection Breast Cancer ScreeningKarkinos HealthcareMarket
Unnamed Breast Cancer ProgramClick TherapeuticsPilot/Phase 2
Lerociclib (Lerocliclib)Chemogenics BioPharmaPhase 3
AT-017Asieris PharmaceuticalsNot Specified
CDK2 inhibitorAcelleraPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Maveropepimut-S (MVP-S)BioVaxysClinical Evaluation
Cannabics® BRST-33CNBX PharmaceuticalsDiscovery